Accelerating Medicines Partnerships® in Type 2 Diabetes and Common Metabolic Diseases: collaborating to maximize the value of genetic and genomic data
In the last two decades, significant progress has been made toward understanding the genetic basis of type 2 diabetes. An important supporter of this research has been the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), most recently through the Accelerating Medicines Partnerships® in Type 2 Diabetes (AMP® T2D) and Common Metabolic Diseases (AMP® CMD). These public-private partnerships between the National Institutes of Health (NIH), multiple biopharmaceutical and life sciences companies, and nonprofit organizations, facilitated and managed by the Foundation for the NIH (FNIH), were designed to improve understanding of therapeutically relevant biological pathways for type 2 diabetes. On the occasion of NIDDK’s 75th anniversary, we review the history of NIDDK support for these partnerships, which saw the convergence of research directions prioritized by academic consortia, the pharmaceutical industry, and government funders. Although the NIDDK was not the sole originator or funder of these efforts, its support and leadership been pivotal to the partnerships’ success and have enabled their research to be broadly accessible through the AMP Common Metabolic Diseases Knowledge Portal (CMDKP) and the AMP Common Metabolic Diseases Genome Atlas (CMDGA). Findings from AMP CMD align with NIDDK’s mission to conduct research and share results with the goal of improving health and quality of life.
